vs

Side-by-side financial comparison of CVRx, Inc. (CVRX) and Linde plc (LIN). Click either name above to swap in a different company.

CVRx, Inc. is the larger business by last-quarter revenue ($16.0M vs $8.8M, roughly 1.8× Linde plc). On growth, Linde plc posted the faster year-over-year revenue change (8.2% vs 4.4%). Linde plc produced more free cash flow last quarter ($898.0K vs $-9.8M). Over the past eight quarters, CVRx, Inc.'s revenue compounded faster (22.0% CAGR vs -96.7%).

CVRx, Inc. is a commercial-stage medical technology company specializing in neuromodulation therapies for chronic cardiovascular diseases. Its flagship Barostim system treats heart failure and resistant hypertension, with core markets across North America and Europe, serving patients unresponsive to conventional drug treatments.

Linde is a global multinational chemical company and the world's largest industrial gas supplier by market share and revenue. Founded by German scientist and engineer Carl von Linde in 1879 in Wiesbaden, Germany, the company is now headquartered in Woking, United Kingdom, and registered in Ireland as Linde plc. Linde plc was formed in 2018 through the merger of Linde AG and Praxair, which was founded in 1907 in the United States as Linde Air Products Company.

CVRX vs LIN — Head-to-Head

Bigger by revenue
CVRX
CVRX
1.8× larger
CVRX
$16.0M
$8.8M
LIN
Growing faster (revenue YoY)
LIN
LIN
+3.8% gap
LIN
8.2%
4.4%
CVRX
More free cash flow
LIN
LIN
$10.7M more FCF
LIN
$898.0K
$-9.8M
CVRX
Faster 2-yr revenue CAGR
CVRX
CVRX
Annualised
CVRX
22.0%
-96.7%
LIN

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
CVRX
CVRX
LIN
LIN
Revenue
$16.0M
$8.8M
Net Profit
$-11.9M
Gross Margin
86.3%
48.5%
Operating Margin
-69.8%
27.8%
Net Margin
-74.5%
Revenue YoY
4.4%
8.2%
Net Profit YoY
-12.0%
EPS (diluted)
$-0.45
$3.98

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CVRX
CVRX
LIN
LIN
Q1 26
$8.8M
Q4 25
$16.0M
$8.8B
Q3 25
$14.7M
$8.6B
Q2 25
$13.6M
$8.5B
Q1 25
$12.3M
$8.1B
Q4 24
$15.3M
$8.3B
Q3 24
$13.4M
$8.4B
Q2 24
$11.8M
$8.3B
Net Profit
CVRX
CVRX
LIN
LIN
Q1 26
Q4 25
$-11.9M
$1.5B
Q3 25
$-12.9M
$1.9B
Q2 25
$-14.7M
$1.8B
Q1 25
$-13.8M
$1.7B
Q4 24
$-10.7M
$1.7B
Q3 24
$-13.1M
$1.6B
Q2 24
$-14.0M
$1.7B
Gross Margin
CVRX
CVRX
LIN
LIN
Q1 26
48.5%
Q4 25
86.3%
Q3 25
86.8%
Q2 25
84.3%
Q1 25
83.5%
Q4 24
83.2%
Q3 24
83.2%
Q2 24
83.9%
Operating Margin
CVRX
CVRX
LIN
LIN
Q1 26
27.8%
Q4 25
-69.8%
23.0%
Q3 25
-83.5%
27.5%
Q2 25
-105.8%
27.7%
Q1 25
-108.8%
26.9%
Q4 24
-67.0%
27.4%
Q3 24
-97.3%
25.0%
Q2 24
-118.3%
26.4%
Net Margin
CVRX
CVRX
LIN
LIN
Q1 26
Q4 25
-74.5%
17.5%
Q3 25
-87.6%
22.4%
Q2 25
-108.4%
20.8%
Q1 25
-111.5%
20.6%
Q4 24
-69.4%
20.8%
Q3 24
-98.0%
18.5%
Q2 24
-118.8%
20.1%
EPS (diluted)
CVRX
CVRX
LIN
LIN
Q1 26
$3.98
Q4 25
$-0.45
$3.28
Q3 25
$-0.49
$4.09
Q2 25
$-0.57
$3.73
Q1 25
$-0.53
$3.51
Q4 24
$-0.39
$3.61
Q3 24
$-0.57
$3.22
Q2 24
$-0.65
$3.44

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CVRX
CVRX
LIN
LIN
Cash + ST InvestmentsLiquidity on hand
$75.7M
$4.0M
Total DebtLower is stronger
$24.7M
Stockholders' EquityBook value
$39.3M
$40.1M
Total Assets
$104.8M
$86.3M
Debt / EquityLower = less leverage
0.62×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CVRX
CVRX
LIN
LIN
Q1 26
$4.0M
Q4 25
$75.7M
$5.1B
Q3 25
$85.1M
$4.5B
Q2 25
$95.0M
$4.8B
Q1 25
$102.7M
$5.3B
Q4 24
$105.9M
$4.8B
Q3 24
$100.2M
$5.2B
Q2 24
$70.4M
$4.6B
Total Debt
CVRX
CVRX
LIN
LIN
Q1 26
$24.7M
Q4 25
$20.7B
Q3 25
$18.6B
Q2 25
$19.7B
Q1 25
$17.6B
Q4 24
$15.3B
Q3 24
$17.5B
Q2 24
$16.9B
Stockholders' Equity
CVRX
CVRX
LIN
LIN
Q1 26
$40.1M
Q4 25
$39.3M
$38.2B
Q3 25
$48.1M
$38.6B
Q2 25
$57.9M
$38.5B
Q1 25
$71.1M
$38.0B
Q4 24
$71.1M
$38.1B
Q3 24
$65.2M
$39.2B
Q2 24
$55.2M
$38.2B
Total Assets
CVRX
CVRX
LIN
LIN
Q1 26
$86.3M
Q4 25
$104.8M
$86.8B
Q3 25
$111.3M
$86.0B
Q2 25
$119.6M
$86.1B
Q1 25
$129.6M
$82.7B
Q4 24
$133.4M
$80.1B
Q3 24
$127.7M
$82.5B
Q2 24
$96.0M
$80.2B
Debt / Equity
CVRX
CVRX
LIN
LIN
Q1 26
0.62×
Q4 25
0.54×
Q3 25
0.48×
Q2 25
0.51×
Q1 25
0.46×
Q4 24
0.40×
Q3 24
0.45×
Q2 24
0.44×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CVRX
CVRX
LIN
LIN
Operating Cash FlowLast quarter
$-9.8M
Free Cash FlowOCF − Capex
$-9.8M
$898.0K
FCF MarginFCF / Revenue
-61.3%
10.2%
Capex IntensityCapex / Revenue
0.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-40.8M
$4.2B

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CVRX
CVRX
LIN
LIN
Q1 26
Q4 25
$-9.8M
$3.0B
Q3 25
$-9.7M
$2.9B
Q2 25
$-7.9M
$2.2B
Q1 25
$-12.8M
$2.2B
Q4 24
$-8.0M
$2.8B
Q3 24
$-10.4M
$2.7B
Q2 24
$-9.8M
$1.9B
Free Cash Flow
CVRX
CVRX
LIN
LIN
Q1 26
$898.0K
Q4 25
$-9.8M
$1.6B
Q3 25
$-10.0M
$1.7B
Q2 25
$-8.0M
$954.0M
Q1 25
$-12.9M
$891.0M
Q4 24
$-8.1M
$1.6B
Q3 24
$-10.4M
$1.7B
Q2 24
$-10.2M
$796.0M
FCF Margin
CVRX
CVRX
LIN
LIN
Q1 26
10.2%
Q4 25
-61.3%
17.9%
Q3 25
-68.1%
19.4%
Q2 25
-59.2%
11.2%
Q1 25
-104.3%
11.0%
Q4 24
-52.5%
18.8%
Q3 24
-78.1%
19.9%
Q2 24
-86.3%
9.6%
Capex Intensity
CVRX
CVRX
LIN
LIN
Q1 26
Q4 25
0.4%
16.6%
Q3 25
2.0%
14.8%
Q2 25
0.8%
14.8%
Q1 25
0.9%
15.7%
Q4 24
0.3%
15.1%
Q3 24
0.3%
12.8%
Q2 24
3.0%
13.7%
Cash Conversion
CVRX
CVRX
LIN
LIN
Q1 26
Q4 25
1.98×
Q3 25
1.53×
Q2 25
1.25×
Q1 25
1.29×
Q4 24
1.63×
Q3 24
1.76×
Q2 24
1.16×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CVRX
CVRX

US$14.9M93%
Other$1.1M7%

LIN
LIN

Segment breakdown not available.

Related Comparisons